[EN] SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)<br/>[FR] PYRIDONES SUBSTITUES INHIBITEURS DE LA POLY(ADP-RIBOSE) POLYMERASE (PARP)
申请人:AVENTIS PHARMA INC
公开号:WO2005097750A1
公开(公告)日:2005-10-20
The present invention discloses and claims a series of 2,3,5-substituted pyridone derivatives as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5'-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
[EN] COMPOUNDS, DERIVATIVES, COMPOSITIONS, PREPARATION AND USES<br/>[FR] COMPOSES, DERIVES, COMPOSITIONS, LEUR PREPARATION ET LEURS UTILISATIONS
申请人:GUILFORD PHARM INC
公开号:WO2003014121A1
公开(公告)日:2003-02-20
This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
本发明涉及化合物、药物组合物以及使用所披露的化合物抑制PARP的方法。
TREATMENT OF CANCER
申请人:Moore Jerome
公开号:US20080103104A1
公开(公告)日:2008-05-01
The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.
Dna damage repair inhibitors for treatment of cancer
申请人:Kudos Pharmaceuticals Limited
公开号:EP2305221A1
公开(公告)日:2011-04-06
The present invention relates to the recognition that inhibition of the base excision repair pathway is selectively lethal in cells which are deficient in HR dependent DNA DSB repair. Methods and means relating to the treatment of cancers which are deficient in HR dependent DNA DSB repair using inhibitors which target base excision repair components, such as PARP, is provided herein.
本发明涉及一种认识,即抑制碱基切除修复途径对缺乏 HR 依赖性 DNA DSB 修复的细胞具有选择性致死作用。本发明提供了使用靶向碱基切除修复成分(如 PARP)的抑制剂治疗缺乏 HR 依赖性 DNA DSB 修复的癌症的方法和手段。